• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Isoniazid for tuberculosis control ineffective in high-risk clusters

bys25qthea
January 26, 2014
in Chronic Disease, Infectious Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD/ Colonies of Mycobacteria organisms

1. Treatment for active tuberculosis (TB) and isoniazid preventive therapy for those at risk did not reduce the overall incidence or prevalence of TB among workers in South African gold mines.

2. Isoniazid may be effective at lowering the incidence of TB during treatment; however, there was a rapid loss of protection once treatment was completed. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Tuberculosis (TB) remains one of the major contributors toward adult deaths. HIV infection, occupational exposure, and close work or living conditions increase the risk of acquiring TB. This study was one of the first to examine a community-level intervention in preventing TB in a high-risk group. The primary endpoint of this study was the incidence of TB up to 12 months after stopping isoniazid. Overall, clusters randomized to the intervention group had a lower incidence of TB during treatment; however, this effect was no longer observed by the time the primary endpoint was measured.

Limitations of this study included variable compliance and retention between the numerous clusters. Further, TB is an airborne pathogen and given that patients could choose to enroll at different times, there was a low proportion of miners taking isoniazid simultaneously in each cluster. Lastly, while most characteristics were well-controlled for between the two groups, HIV status was self-reported in this study and this may have inadvertently biased the results. Nevertheless, this study elucidated the need for a more effective way to manage latent TB in order to minimize the risk of future activation.

Click to read the study in NEJM

RELATED REPORTS

Oral BPaLM regimen is noninferior to standard of care for rifampin-resistant tuberculosis

Two bedaquiline-containing regimens had superior efficacy and safety profiles for treatment of rifampin-resistant tuberculosis

#VisualAbstract: All-oral regimen with delamanid, linezolid, levofloxacin, and pyrazinamide is effective for fluoroquinolone-sensitive multidrug-resistant tuberculosis

Click to read an accompanying editorial in NEJM

In-Depth [cluster-randomized controlled trial]: This study involved fifteen clusters of workers (n=78,744) from three gold-mining companies in South Africa. Workers were assigned to a cluster based on their employer and location. Each cluster was then randomized to either intervention or no intervention. The intervention consisted of TB screening and referral for treatment if active TB was diagnosed. Nine months of isoniazid preventive therapy was offered to those who were not diagnosed with active TB. The majority of participants were male (97.6%). At 12 months after the intervention ended, the incidence of TB in the intervention and control clusters was 3.02 and 2.95 per 100 person-years, respectively (adjusted rate ratio, 0.96; 95% CI, 0.76 to 1.21; P=0.71). During the initial 9-month follow-up period, the incidence of TB was significantly lower among the intervention clusters than the control clusters; however, the incidence was similar in the two groups following this period.

By Jonathan Liu, MD and Adrienne Cheung

More from this author: SSRI use during pregnancy not linked to increased risk of autism Combo antifungal therapy most effective treatment for cryptococcal meningitis, Rhinovirus, genes may interact to increase risk of childhood asthma, Functional MRI map for physical pain identified Glutamine and antioxidant supplementation provide no benefit for critically-ill patients New Hepatitis C virus (HCV) treatment effective  

© 2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: Isoniazidtuberculosis
Previous Post

Bapineuzumab does not improve clinical outcomes in Alzheimer’s disease

Next Post

Prone sleeping position and heavy bedding associated with SIDS [Pediatrics Classics Series]

RelatedReports

Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]
Chronic Disease

Oral BPaLM regimen is noninferior to standard of care for rifampin-resistant tuberculosis

January 4, 2023
Quick Take: Discovery and validation of a prognostic proteomic signature for tuberculosis progression
Chronic Disease

Two bedaquiline-containing regimens had superior efficacy and safety profiles for treatment of rifampin-resistant tuberculosis

December 7, 2022
#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival
StudyGraphics

#VisualAbstract: All-oral regimen with delamanid, linezolid, levofloxacin, and pyrazinamide is effective for fluoroquinolone-sensitive multidrug-resistant tuberculosis

November 30, 2022
Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Chronic Disease

All-oral regimen with delamanid, linezolid, levofloxacin, and pyrazinamide is effective for fluoroquinolone-sensitive multidrug-resistant tuberculosis

November 8, 2022
Next Post

Prone sleeping position and heavy bedding associated with SIDS [Pediatrics Classics Series]

A quarter of youths with assault injury own a gun

Firearm-related hospitalizations in children represent a heavy burden

Gestational weight loss may improve outcomes for obese women

Current BMI standards may be predictive of metabolic syndrome

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options